C07K 14/145
Rhabdoviridae
Official title: Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
C07K14/145 (Rhabdoviridae) appears on 10 US grants and 19 published applications in this corpus.
Search patents in C07K- Granted patents
- 10
- Published applications
- 19
- Assignees
- 22
- Inventors
- 52
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 4 |
| 2020 | 2 | 0 |
| 2021 | 1 | 4 |
| 2022 | 0 | 0 |
| 2023 | 2 | 0 |
| 2024 | 0 | 6 |
| 2025 | 4 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccine composition for preventing rabies, and preparation method thereof15 Jul 2025US 12,357,685 B2Bioapplications Inc.
- Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins27 May 2025US 12,311,021 B2International AIDS Vaccine Initiative
- Mutated polypeptides, compositions comprising the same, and uses thereof18 Mar 2025US 12,252,512 B2Interius Biotherapeutics, Inc.
- Self-inactivating rabies virus vector encoding a nucleoprotein and degron21 Jan 2025US 12,203,092 B2Mironid Limited
- Attenuated strains of oncolytic rhabdovirus and uses thereof in tumor treatment22 Aug 2023US 11,732,012 B2Fantasia Biopharma (Zhejiang) Co. Ltd
- Mutant vsvg and targeting vector13 Aug 2026US 2026/0234198 A1Shenzhen Genocury Biotech Co., Ltd.
- Compositions and Methods for Targeted Delivery of CRISPR-CAS Effector Polypeptides19 Feb 2026US 2026/0048143 A1The Regents of the University of California
- Mutated polypeptides, compositions comprising the same, and uses thereof24 Jul 2025US 2025/0236647 A1Interius Biotherapeutics, Inc.
- Self-replicating rna molecules and application thereof5 Dec 2024US 2024/0401076 A1
- Vaccine Compositions For Preventing Coronavirus Disease14 Nov 2024US 2024/0374710 A1
Most cited
By later US patents